The primary end point significantly increased in the treatment group compared with the placebo group ( 61.5 % vs 7.4 % ; P < 0.001 ) , as well as 1,25 ( OH ) 2D levels ( 22.5 [ IQR , 15-26 ] vs 11 [ IQR , 10-15 ] pg/mL ; P < 0.001 ) and the proportion of patients achieving the target calcium level ( 76.9 % vs 48.2 % ; P = 0.03 ) .